StemCell Therapy

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company'shistory.

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes.

Bachem moves its headquarters to the Swiss town of Bubendorf,with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150.

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988.

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance.

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients. By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day.

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services.

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion.

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas.

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the companys history. Sales are over the 200 million mark for the first time at 236.5 million CHF.Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K.

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future.

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and 272 new employees are hired.

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are plans to continue expanding.

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Read the original:
Dexcom: changing the lives of people with type 1 diabetes | Medical Devices & Pharma - Healthcare Global - Healthcare News, Magazine and Website

FOR IMMEDIATE RELEASE:June 22, 2021

MEDIA CONTACTS:Dan Tierney: 614-644-0957 Breann Almos: 614-644-0957

Governor DeWine Signs Bills Into Law

(COLUMBUS, Ohio)Ohio Governor Mike DeWine today was joined by Senate Bill 21 sponsors and several stakeholders for a bill signing at the Ohio Statehouse.

Senate Bill 21, sponsored by Senator Nickie Antonio and Senator Nathan Manning, requires the Board of Emergency Medical, Fire, and Transportation Services to adopt guidelines for the assessment, triage, and transport of stroke patients to hospitals. The bill requires emergency service organizations to establish stroke protocols and provide training based on the boards guidelines.

Following the ceremony in private, Governor DeWine signed Senate Bill 42, sponsored by Senator Tim Schaffer, into law. The bill establishes the second week of November as Ohio Diabetes Awareness-Heart Connection Week to raise public awareness about the connection between diabetes and cardiovascular disease.

30

Continue reading here:
Governor DeWine signs bills for stroke protocols, public awareness for diabetes and cardiovascular disease - Ohio Department of Health

In his recently-published memoir, Making Excellence a Habit, Dr V Mohan recalls his experience of setting up one of the worlds largest chains of diabetes centres, Dr Mohans Group of Diabetes Institutions that began as a single clinic in 1991 and now has over 52 branches across 32 cities.

Dr V Mohan began researching on diabetes with his father, Prof. M. Viswanathan, when he was just 18.

India is home to 77 million people with diabetes and 80 million people with prediabetes. By 2030, the diabetic population in the country is close to hitting the mark of 101 million. Studies show that almost every Indian past the age of 50 is a diabetic unless proven otherwise, and at this rate it could become the next diabetes capital of the world soon, overtaking China. Dr V Mohan, who has done some stellar work over the last five decades in

BY

ET Online

AbcSmall

AbcMedium

AbcLarge

Introductory Offer

99 for 2 months

Then 2,499 for 1 year (208 per month)

Subscribe Now

(Credit card mandatory)

You can cancel your subscription anytime

Yearly

2499

15 Days Trial

Subscribe Now

(Pay Using Netbanking/UPI/Debit Card)

399/month

Monthly PLAN

Billed Amount 399

208/month

(Save 49%)

Yearly PLAN

Billed Amount 2,499

15 Days Trial +Includes DocuBay and TimesPrime Membership.

150/month

(Save 63%)

2-Year PLAN

Billed Amount 3,599

15 Days Trial +Includes DocuBay and TimesPrime Membership.

Already a Member? Sign In now

Special Offer on ET Prime

Subscribe to ET Prime - Get Flat 20% Off

Special Offer on ET Prime

Subscribe to ET Prime - Get Flat 25% Off

Special Offer on ET Prime

Subscribe to ET Prime - Get Flat 25% Off

Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

Stock analysis. Market Research. Industry Trends on 4000+ Stocks

Clean experience withMinimal Ads

Comment & Engage with ET Prime community

Exclusive invites to Virtual Events with Industry Leaders

A trusted team of Journalists & Analysts who can best filter signal from noise

The rest is here:
'In India, 50% people with diabetes are not even aware they have the condition' - Economic Times

Photo: Photo of Artem Podrez in Pexels / Pexels

Diabetes is an issue that will never go unnoticed. Especially in recent years that we have had the opportunity to have more information and thus worry more about our health. The truth is that it is one of the most alarming chronic diseases today: it contributes to 10-15% of deaths in the United States. In addition, there are updated data from the World Health Organization (WHO), in which it is confirmed that in 2019 diabetes was the direct cause of 1.5 million deaths.Also the total of cases is increasing, it is estimated that almost 1.6 million Americans are diagnosed with diabetes each year. As if that werent enough, recent research led by the Johns Hopkins Bloomberg School of Public Health found disappointing data: the percentage of American adults with diabetes who achieved glycemic control it worsened between 2007 and 2010, and again between 2015 and 2018.

As expected, these findings come to emphasize even more (especially after a year of pandemic), the continuing challenges that arise in the control of diabetes. According to the study authors, it is time to take more control of the situation, it is no joke to say that diabetes is one of the most prevalent health conditions and in many cases it is directly related to controllable factors. The team used data from an annual government-sponsored health study to assess trends in blood sugar control among adults with diabetes, as well as the control of blood pressure and cholesterol.

It is well known that type 2 diabetes is the most common form of the disease and is strongly related to diet and lifestyle factors. According to the study, it is estimated that affects more than 13% of the adult population in the United States and it increases the risks of other serious diseases, especially cardiovascular ones. Based on this, traditional approaches to diabetes care are aspects focused on reducing chronic high blood sugar / glucose, maintaining blood pressure below levels considered hypertension and good cholesterol control. . In addition to aspects related to lifestyle; Unfortunately the study shows that most people do not have this disease under control.

According to information released in the study: the proportion of adults with glycemic control improved between 1999 and 2007, but then it fell from 57.4% to 50.5% between 2007 and 2018. In addition, the study authors also observed a decrease in the proportion of people who achieved blood pressure control. It is worth mentioning that the proportion that achieved adequate cholesterol control stabilized.

Elizabeth Selvin, lead author of the study and professor in the Department of Epidemiology at the Bloomberg School, stated in the press release that it is rather disturbing findings. There has been a real decline in glycemic control over the past decade, and overall, only a small proportion of people with diabetes are simultaneously meeting the key goals of glycemic control, blood pressure control, and high cholesterol control.

The researchers had access to data including interviews and clinical examinations of approximately 5000 people nationwide. The sample consisted of 6,653 survey participants from 1999 to 2018 who were at least 20 years old, not pregnant, and reported having been diagnosed with diabetes outside of pregnancy.

Among the most relevant data that occurred between 1999 and 2010: the percentage of respondents who achieved glycemic control, defined as HbA1c levels below 7.0%, increased from 44% to 57.4%. However, it dropped dramatically between 2015 and 2018. Something similar happened with blood pressure: it rose steadily from 64% between 1999 and 2002 to 74.2% between 2011 and 2014, then fell to 70.4% between 2015 and 2018. Finally, the percentage of people with diabetes who controlled their lipoprotein cholesterol high-density (non-HDL) increased from 25.3% between 1999 and 2002 to 52.3% between 2007 and 2010, but then reached only 55.7% between 2015 and 2018.

In conclusion, the researchers discovered that the proportion of people who managed to control the 3 risk factors increased from 9% between 1999 and 2002, to 24.9% between 2007-2010. And then it was reduced to 22.2% between 2015 and 2018. Another of the authors who led the study Michael Fang spoke about it, who stated that the trends uncovered in the study are a wake-up call. Well, they point out that millions of Americans with diabetes have a higher risk of serious complications, that is, the study suggests that the worsening of diabetes control may already be having a detrimental effect at the national level.

Another highly relevant aspect suggested by the studys findings is that something changed since 2010 and that it had an influence by delaying progress in controlling diabetes risk factors. Based on this, the researchers undertook the task of analyzing two large clinical trials, published in 2008. In which they found that the intensive reduction of HbA1c to very low levels did not lead to the cardiovascular benefits that people expected, and some trial participants saw a increased risk of hypoglycemia. It is worth mentioning that to date things have changed, that is, it was in 2008 when the results of these trials were published; today the market offers numerous new and improved diabetes medications. Which if they allow reducing HbA1c (glycosylated hemoglobin test, a blood test for type 2 diabetes and prediabetes) and without causing hypoglycemia.

Although much research work remains to be done, these types of studies come to give greater clarity to medical personnel and enrich strategies in the management of diabetes. Which should not only be focused solely on one optimal glycemic control of patients with diabetes, it is necessary to integrate the good management of risk factors, make adjustments in lifestyle, diet, stress levels and sleep cycles.

It may interest you:

eldiariony.com

See more here:
Diabetes: why Americans have such a hard time controlling blood sugar - The Saxon

Lille, France; Cambridge, MA; June 23, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced it will be making two poster presentations at two internationally-renown scientific and medical events in June 2021, including a thought-leadership documentary featuring Key Opinion Leaders (KOLs).

A poster presentation looking at the effects of age on the clinical performance of GENFITs proprietary diagnostic technology NIS4 in diagnosing at-risk NASH in patients with type 2 diabetes in comparison to a number of non-invasive tests, will be presented at the International Liver Congress 2021 on June 23-26, 2021, organized by the European Association for the Study of the Liver (EASL).

A poster presentation providing key insights into the performance of NIS4 technology either alone or in combination with other blood-based non-invasive tests in identifying at-risk NASH and advanced fibrosis in patients with and without type 2 diabetes, will be presented at the 81st Scientific Sessions of the American Diabetes Association (ADA) on June 25-29, 2021.

In addition, GENFIT is a key contributor to a thought-leadership documentary for ADA TV discussing, alongside KOLs, the link between NASH and patients with type 2 diabetes and how access to non-invasive diagnostic test kits to diagnose NASH, such as NASHnext, powered by GENFITs NIS4 technology, could provide an alternative to costly and invasive procedures and potentially benefit millions of patients. Featured KOLs include:

To view the 5-minute thought-leadership documentary, please click on the following link: https://www.youtube.com/watch?v=MlBoAG5tFMEv

Both events will be held virtually and the full programs can be found on the American Diabetes Association website and on the International Liver Congress website.

POSTER PRESENTATIONS

International Liver Congress June 23-26, 2021

Title: In Type 2 Diabetic Patients, the Identification of At-risk Nash is Impacted by Age: A Comparison of Serum-Based NITS Including NIS4

Abstract number: 2739

Poster identifier: PO-2739

Authors: Vlad Ratziu, Jeremy Magnanensi, Sylvie Deledicque, Elodie Delecroix, Yacine Hajji, Christian Rosenquist, Suneil Hosmane and Arun Sanyal.

81st Scientific Sessions of the ADA

Title: Application of NIS4 Technology for Stand-alone and Sequential Identification of At-risk NASH or Advanced Fibrosis in Non-Diabetic and Type 2 Diabetic Patients

Abstract number: #2021-A-5594-Diabetes

Poster number: 1174-P (Category 21-C Integrated PhysiologyLiver)

Authors: Christian Rosenquist, Yacine Hajji, Jrmy Magnanensi, Nicolas Stankovic-Valentin, Suneil Hosmane and Arun J. Sanyal

ABOUT THE INTERNATIONAL LIVER CONGRESS

The International Liver Congress is an annual congress and EASLs flagship event, attracting scientific and medical experts from around the world to learn about the latest in liver research.

ABOUT THE ADA

The ADA is the US leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. It holds annual scientific sessions to bring together the latest, cutting-edge advances in diabetes research, prevention and care.

ABOUT NIS4

NIS4 is GENFITs non-invasive, blood-based diagnostic technology, which was developed to identify patients with non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis (F>2), also referred to as at-risk NASH. In January 2019, GENFIT signed a licensing agreement with Labcorp to make NIS4 technology available for use in clinical research through their drug development subsidiary, Covance. In September 2020, GENFIT signed another licensing agreement with Labcorp to commercialize NIS4 in the US and Canada as a Laboratory Developed Test. Since April 2021, Labcorp has made NASHnext, powered by NIS4, available for use in the clinic. GENFIT also continues to explore opportunities to obtain formal marketing authorization of an in vitro diagnostic (IVD) test supported by NIS4 technology in both the U.S. and European markets. For more information, please visit: https://nis4.com.

ABOUT NASH

NASH is a liver disease characterized by an accumulation of fat (lipid droplets), along with inflammation and degeneration of hepatocytes. The disease is associated with an increased risk of cardiovascular disease along with long-term risk for progression to cirrhosis, leading to liver insufficiency and potential progression to liver cancer. NASH is a serious disease that often carries no symptoms in its early stages, but if left untreated can result in cirrhosis, cancer, and the need for liver transplant. The prevalence of NASH is rapidly increasing as a result of the growing obesity and diabetes epidemics and is believed to affect as much as 12 percent of people in the U.S. and six percent worldwide.

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). Elafibranor is an investigational compound that has not been reviewed and has not received approval by any regulatory authority. As part of GENFITs comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronexts regulated market in Paris (Nasdaq and Euronext: GNFT). http://www.genfit.com

GENFIT FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the performance of NIS4 technology in the detection of NASH and at-risk NASH in non-diabetic and type 2 diabetic patients, the performance of NIS4 technology relative to other technologies, the potential for diagnostic tests powered by NIS4 technology to play a critical role in the diagnosis and management of patients with NASH, the potential for non-invasive testing to gain importance and the capability of NIS4 technology to identify patients who may require medical intervention, the development plans for NIS4 in the U.S. and in Europe and timing of such development plans, and the potential to obtain formal marketing authorization of an IVD test supported by NIS4 technology in the U.S. and/or European markets. The use of certain words, including consider, contemplate, think, aim, expect, understand, should, aspire, estimate, believe, wish, may, could, allow, seek, encourage or have confidence or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Companys management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange rate fluctuations and the Companys continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Companys public filings with the French Autorit des Marchs Financiers (AMF), including those listed in Chapter 2 Main Risks and Uncertainties of the Companys 2020 Universal Registration Document filed with the AMF on 23 April 2021 under n D.21-0350, which is available on the Companys website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (SEC) including the Companys 2020 Annual Report on Form 20-F filed with the SEC on April 23, 2021. In addition, even if the Companys results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACT

GENFIT | Investors

Tel: +1 (617) 714 5252 | investors@genfit.com

PRESS RELATIONS | Media

Stephanie Boyer Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

GENFIT | 885 Avenue Eugne Avine, 59120 Loos - FRANCE | +333 2016 4000 | http://www.genfit.com

Excerpt from:
GENFIT presents new NIS4 data in NASH at the International Liver Congress and the 81st Scientific - GlobeNewswire

Led by John Buse, MD, PhD, and Anna Kahkoska, MD, PhD, this analysis showed that GLP1-RA and SGLT2i medication use for type 2 diabetes of hospitalized COVID-19 patients was associated with lower odds of mortality and other adverse outcomes.

CHAPEL HILL, NC Diabetes is one of the comorbidities most strongly associated with severe coronavirus disease 2019 (COVID-19) in the United States, and data from early in the pandemic suggested individuals with type 2 diabetes faced twice the risk of death from COVID-19, as well as a greater risk of requiring hospitalization and intensive care.

The National COVID Collaborative (N3C), a partnership of NIH Clinical and Translational Science Award Program hubs, conducted a study of data from 12,446 individuals with type 2 diabetes who had a positive test for COVID-19 in 2020. These scientists found that individuals who had been treated with certain kinds of diabetes medications fared better than those who were treated with a different type of medication.

This research was published in Diabetes Care, the journal of the American Diabetes Association. The senior author is John Buse, MD, PhD, Co-Director of the North Carolina Translational and Clinical Sciences (NC TraCS) Institute at UNC and lead of the UNC Diabetes Research Center. The first author is Anna Kahkoska, MD, PhD, assistant professor in the UNC Department of Nutrition at the UNC Gillings School of Global Public Health and the UNC School of Medicine.

Two classes of medications that lower blood sugar glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodiumglucose cotransporter 2 inhibitors (SGLT2i) have been associated with a reduction of cardiorenal events and mortality in previous large trials of cardiovascular, heart failure, and renal outcomes, in populations at high risk of cardiorenal events. Benefits associated with these medications appear most pronounced among individuals with type 2 diabetes and comorbid cardiovascular disease, heart failure, chronic kidney disease, and obesity, conditions that also incur the highest risk for severe COVID-19.

Additionally, scientists have speculated about plausible mechanisms for the protective effects of GLP1-RA and SGLT2i in COVID-19, independent of their glycemic effects. Yet, it is not known how the use of new medications is associated with severity of COVID-19.

Our objective was to characterize the association of premorbid use of GLP1-RA and SGLT2i with COVID-19 outcomes, said Buse, who is the Verne S. Caviness Distinguished Professor of Medicine and endocrinology division chief at the UNC School of Medicine. The study hypothesis was that use of both classes of medications would be associated with improved outcomes in the setting of COVID-19 infection. And characterizing these associations could reveal treatment strategies to improve outcomes for a population at high risk for COVID-19associated mortality.

For the study, the researchers selected individuals using dipeptidyl peptidase 4 inhibitors (DPP4i) as a comparator group to individuals taking GLP1-RA or SGLT2i medications because DPP4i medications can also be considered for second-line use after the initiation of metformin and have been suggested to be safe or beneficial in COVID-times in other real-world analyses.

To determine the respective associations of premorbid glucagon-like peptide-1 receptor agonist (GLP1-RA) and sodiumglucose cotransporter 2 inhibitor (SGLT2i) use, compared with premorbid dipeptidyl peptidase 4 inhibitor (DPP4i) use, with severity of outcomes in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Of the 12,446 individuals, the 60-day mortality was 3.11%, with 2.06% for GLP1-RA use, 2.32% for SGLT2i use, and 5.67% for DPP4i use. Both GLP1-RA and SGLT2i use were associated with lower 60-day mortality compared with DPP4i use. Use of both GLP1-RA and SGLT2i medications was also associated with decreased total mortality, emergency room visits, and hospitalizations, though the individuals taking DPP4i medications were older and generally sicker.

N3C is a COVID research platform funded by the National Institute of Healths National Center for Advancing Translational Sciences (NCATS) including data on over 2 million people with a positive COVID test.The North Carolina Translational and Clinical Sciences (TraCS) Institute played an integral role in the development of N3C and supports efforts to use the data to develop better treatment and prevention programs for COVID.

Other authors of the Diabetes Care paper are Trine Julie Abrahamsen, G. Caleb Alexander, Tellen D. Bennett, Christopher G. Chute, Melissa A. Haendel, Klara R. Klein, Hemalkumar Mehta, Joshua D. Miller, Richard A. Moffitt, Til Strmer, and Kajsa Kvist.

Read the original post:
UNC Researchers Lead Study of Diabetes Treatment of Severely Ill COVID-19 Patients | Newsroom - UNC Health and UNC School of Medicine

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter Stem Cell Characterization Panel for the analysis and optimization of stem cell lines used in the development of potential novel therapeutics.

Recent breakthroughs in stem cell therapy, regenerative medicine, and CRISPR engineering have advanced the development of promising new treatments for debilitating diseases across a broad range of research areas, including neurological and cardiovascular disease, vision loss, and certain types of cancers. However, one of the biggest challenges with stem cell research is the high variability found within the development and manufacturing process that impacts the ability of the stem cells to differentiate and function. The new nCounter Stem Cell Characterization panel measures the eight essential components of stem cell biology and provides a novel, standardized assay for evaluating factors that influence and determine viability, functionality, and pluripotency.

"The simple, automated workflow and highly reproducible, digital results make the nCounter system an excellent fit for all types of stem cell applications," said Chad Brown, senior vice president of Sales and Marketing at NanoString. "With this panel, researchers have a powerful new tool that can quickly assess stem cell health to advance development efforts and optimize stem cell production, achieving robust results in less than 24 hours."

"The Process Development team at ARMI-BioFabUSA is very excited to use the nCounter Stem Cell Characterization panel across a number of our projects where we are developing human tissues composed of mature cells differentiated from stem cells. The Stem Cell Characterization Panel will give us greater insight into the differentiation status of our cells and the success of our current process development and manufacturing runs," said Damian Hile, senior process development scientist at Advanced Regenerative Manufacturing Institute-BioFabUSA (ARMI-BioFabUSA).

The novel 770 gene panel is available for humans and mice and was designed at NanoString with input from leading stem cell experts. To learn more about the nCounter Stem Cell Characterization Panel, visit NanoString at the virtual 2021 ISSCR Conference June 21-26. In addition, NanoString is sponsoring the Cellular Identity: Pluripotency Dynamics session, with Joseph Beechem, Ph.D., chief scientific officer at NanoString.

To learn more about the panel and how the development of the panel can expedite stem cell research, visit the Brief nCounters stem cell experience.

About ARMI-BioFabUSA

The Advanced Regenerative Manufacturing Institute (ARMI), headquartered in Manchester, NH, is an organization funded by the United States Department of Defense. ARMI's mission is to make practical the large-scale manufacturing of engineered tissues and tissue-related technologies to benefit existing industries and grow new ones. ARMI brings together a consortium of over 150 partners from across the industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs. For more information on ARMI-BioFabUSA, please visit http://www.ARMIUSA.org.

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company's nCounter Analysis System is used in life sciences research and has been cited in more than 4,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's GeoMx Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

For more information, please visit http://www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Read more:
NanoString Launches nCounter Stem Cell Characterization Panel to Advance the Development of Stem Cell Therapy - Business Wire

Adipose Tissue Derived Stem Cell Therapy Market study by The Insight Partners provides details about the market dynamics affecting the market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favorable competitive landscape and trends prevailing over the years.

The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Adipose Tissue Derived Stem Cell Therapy market during the forecast period, i.e., 20212028. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market to offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries.

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Adipose Tissue Derived Stem Cell Therapy market. The researcher provides an extensive analysis of the Adipose Tissue Derived Stem Cell Therapy market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

Get Sample Report of Adipose Tissue Derived Stem Cell Therapy Market Report @ https://www.theinsightpartners.com/sample/TIPRE00014843/

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

The Adipose Tissue-derived Stem Cell Therapy Market is growing due to increasing use of regenerative medicine in disease treatment and increasing private and public funding for stem cell therapy. However, high cost associated with stem cell processing hampers growth of this market.

Competitive scenario:

The study assesses factors such as segmentation, description, and applications of Adipose Tissue Derived Stem Cell Therapy industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.

The final report will add the analysis of the Impact of Covid-19 in this report Adipose Tissue Derived Stem Cell Therapy Market.

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Adipose Tissue Derived Stem Cell Therapy Market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Adipose Tissue Derived Stem Cell Therapy Market is analyzed and depicted in the report.

Some of the companies competing in the Adipose Tissue Derived Stem Cell Therapy Market are

Segmentation

The Adipose Tissue-derived Stem Cell Therapy market is segmented on the basis of cell type, product, disease and end user. Based on cell type, the market is segmented as autologous stem cells, allogeneic stem cells. On the basis of product, the market is categorized as cell line and culture media. Based on disease the market is segmented into cancer, obesity, wounds and injuries, musculoskeletal diseases, cardiovascular diseases and others. Based on end user the market is segmented into hospitals and trauma centers , cell banks and tissue banks , research laboratories and academic institutes and other The market is also segmented according to region. The Adipose Tissue Derived Stem Cell Therapy Market has been segmented into Latin America, North America, Asia Pacific, Europe, and the Middle East & Africa on the basis of region

Research Methodology

The report has its roots definitely set in thorough strategies provided by the proficient data analysts. The research methodology involves the collection of information by analysts only to have them studied and filtered thoroughly in an attempt to provide significant predictions about the market over the review period. The research process further includes interviews with leading market influencers, which makes the primary research relevant and practical. The secondary method gives a direct peek into the demand and supply connection. The market methodologies adopted in the report offer precise data analysis and provides a tour of the entire market. Both primary and secondary approaches to data collection have been used. In addition to these, publicly available sources such as SEC filings, annual reports, and white papers have been used by data analysts for an insightful understanding of the market. The research methodology clearly reflects an intent to extract a comprehensive view of the market by having it analyzed against many parameters. The valued inputs enhance the report and offer an edge over the peers.

Drivers & Constraints

The Adipose Tissue Derived Stem Cell Therapy Market rests united with the incidence of leading players who keep funding to the markets growth significantly every year. The report studies the value, volume trends, and the pricing structure of the market so that it could predict maximum growth in the future. Besides, various suppressed growth factors, restraints, and opportunities are also estimated for the advanced study and suggestions of the market over the assessment period.

Adipose Tissue Derived Stem Cell Therapy Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00014843/

Thanks for reading this release; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact US:

Call: +1-646-491-9876

Email: sales@theinsightpartners.com

View original post here:
Adipose Tissue Derived Stem Cell Therapy Market New Innovation and Perception 2028 AlloCure, Antria, Celgene, Cellleris SA, Corestem, Intrexon,...

REDWOOD CITY, Calif. and NEW YORK and BASEL, Switzerland, June 21, 2021 /PRNewswire/ --Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, andAruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that they have entered a non-exclusive research collaboration to evaluate the use of JSP191, Jasper's anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning agent with ARU-1801, Aruvant's investigational lentiviral gene therapy for sickle cell disease (SCD). The objective of the collaboration is to evaluate the use of JSP191 as an effective and more tolerable conditioning agent that can expand the number of patients who can receive ARU-1801, a potentially curative treatment for SCD.

"This research collaboration with Aruvant is the first to use a clinical-stage antibody-based conditioning agent and a novel clinical-stage gene therapy, giving this combination a clear advantage by moving beyond the harsh conditioning agents currently used for gene therapy and establishing this next-generation potentially curative treatment as a leader in sickle cell disease," said Kevin N. Heller, M.D., executive vice president, research and development of Jasper. "Our goal is to establish JSP191 as a potential new standard of care conditioning agent, broadly in autologous gene therapy and allogeneic hematopoietic stem cell transplantation."

Gene therapies and gene editing technologies generally require that a patient's own hematopoietic stem cells first be depleted from the bone marrow to facilitate the engraftment of the new, gene-modified stem cells through a process called conditioning. Other investigational gene therapies and gene editing approaches in SCD use a high-dose chemotherapy such as busulfan for the conditioning regimen, which can place patients at prolonged risk for infection and bleeding, secondary malignancy and infertility. ARU-1801 is currently the only gene therapy that has demonstrated durable efficacy using both a lower dose of chemotherapy and a different agent than busulfan with a more limited side effect profile. The Aruvant-Jasper partnership is focused on evaluating the potential of using JSP191, a highly targeted anti-CD117 (stem cell factor receptor) monoclonal antibody agent, as the foundationof a novel conditioning regimen for use in combination with ARU-1801 to further reduce the negative side effects while maintaining efficacy.

"The unique attributes of ARU-1801 enable us to bring a potentially curative one-time therapy to individuals with sickle cell disease that can be delivered in the safest way possible," said Will Chou, M.D., Aruvant chief executive officer. "By partnering with Jasper to evaluate the use of JSP191 with ARU-1801, we are one step closer to developing a next-generation definitive therapy with an even more patient-friendly conditioning regimen. We believe that this combination may be able to further expand the number of patients who can benefit from ARU-1801 in the future, including potentially those with more moderate disease."

About JSP191 JSP191 is a humanized monoclonal antibody in clinical development as a conditioning agent that blocks stem cell factor receptor signaling leading to clearance of hematopoietic stem cells from bone marrow, creating an empty space for donor or gene-corrected transplanted stem cells to engraft. While hematopoietic cell transplantation can be curative for patients, its use is limited because standard high dose myeloablative conditioning is associated with severe toxicities and standard low dose conditioning has limited efficacy. To date, JSP191 has been evaluated in more than 90 healthy volunteers and patients. It is currently enrolling in two clinical trials for myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) and severe combined immunodeficiency (SCID) and expects to begin enrollment in four additional studies in 2021 for severe autoimmune disease, sickle cell disease, chronic granulomatous disease and Fanconi anemia patients undergoing hematopoietic cell transplantation.

About ARU-1801 ARU-1801 is designed to address the limitations of current curative treatment options, such as low donor availability and the risk of graft-versus-host disease (GvHD) seen with allogeneic stem cell transplants. Unlike investigational gene therapies and gene editing approaches which require fully myeloablative conditioning, the unique characteristics of ARU-1801 allow it to be given with reduced intensity conditioning ("RIC"). Compared to myeloablative approaches, the lower dose chemotherapy regimen underlying RIC has the potential to reduce not only hospital length of stay, but also the risk of short- and long-term adverse events such as infection and infertility. Preliminary clinical data from the MOMENTUMstudy, an ongoing Phase 1/2 trial of ARU-1801 in patients with severe sickle cell disease, demonstrate continuing durable reductions in disease burden.

The MOMENTUM Study Aruvant is conducting the MOMENTUM study, which is evaluating ARU-1801, a one-time potentially curative investigational gene therapy for patients with SCD. This Phase 1/2 study is currently enrolling participants, and information may be found at momentumtrials.comwhich includes a patient brochure, an eligibility questionnaireand information for healthcare providers.

About Jasper Therapeutics Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, a first-in-class anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable safer and more effective curative allogeneic and autologous hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing its preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.

About Aruvant Sciences Aruvant Sciences, part of the Roivant family of companies, is a clinical-stage biopharmaceutical company focused on developing and commercializing gene therapies for the treatment of rare diseases. The company has a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. Aruvant has an active research program with a lead product candidate, ARU-1801, in development for individuals suffering from sickle cell disease (SCD). ARU-1801, an investigational lentiviral gene therapy, is being studied in a Phase 1/2 clinical trial, the MOMENTUM study, as a one-time potentially curative treatment for SCD. Preliminary clinical data demonstrate engraftment of ARU-1801 and amelioration of SCD is possible with one dose of reduced intensity chemotherapy. The company's second product candidate, ARU-2801, is in development to cure hypophosphatasia, a devastating, ultra-orphan disorder that affects multiple organ systems and leads to high mortality when not treated. Data from pre-clinical studies with ARU-2801 shows durable improvement in disease biomarkers and increased survival. For more information on the ongoing ARU-1801 clinical study, please visit http://www.momentumtrials.comand for more on the company, please visit http://www.aruvant.com. Follow Aruvant on Facebook, Twitter @AruvantSciencesand on Instagram @Aruvant_Sciences.

About Roivant Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants nimble and focused biopharmaceutical and health technology companies. For more information, please visit http://www.roivant.com.

SOURCE Aruvant Sciences andJasper Therapeutics

Home

See the original post:
Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene...

New York, June 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Devices Industry" - https://www.reportlinker.com/p05957490/?utm_source=GNW The rapid rise in the incidence of nerve injuries worldwide, increasing prevalence of various neurological disorders, especially in the expanding elderly population, and development of advanced technology-based nerve repair and regeneration products are fueling growth in the global market. The constant increase in incidence of nerve injuries is leading to high demand for nerve repair and regeneration products. The growing incidence of chronic nervous system disorders such as Parkinson`s and Alzheimer`s disease is also driving demand for nerve repair and regeneration procedures and devices. There is also increased funding for clinical trials aimed at development of effective and safe therapies for treatment of various neurological disorders. Initiatives such as stem cells in umbilical blood infusion for cerebral palsy; and the use of Polyethylene glycol (PEG) drug for promoting axonal fusion technique for repairing peripheral nerve injuries are favoring market growth.

- Amid the COVID-19 crisis, the global market for Nerve Repair and Regeneration Devices estimated at US$6.6 Billion in the year 2020, is projected to reach a revised size of US$11.8 Billion by 2026, growing at a CAGR of 10% over the analysis period. Neurostimulation & Neuromodulation Devices, one of the segments analyzed in the report, is projected to grow at a 9.7% CAGR to reach US$10.9 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Biomaterials segment is readjusted to a revised 11.7% CAGR for the next 7-year period. This segment currently accounts for a 13.8% share of the global Nerve Repair and Regeneration Devices market. The neurostimulation and neuromodulation devices segment growth will be fueled by rising incidence of peripheral nerve injuries, development of technologically advanced products and favorable reimbursement scenario. Within the segment, internal neurostimulation and neuromodulation devices category is being driven due to the devices` ability to lower occurrence of post-surgical complications and reducing duration of hospitalization. Biomaterials segment is expected to witness high growth, driven by broadening application range, increased availability of government funding for innovations, and development of advanced products.

The U.S. Market is Estimated at $2.2 Billion in 2021, While China is Forecast to Reach $1.8 Billion by 2026

- The Nerve Repair and Regeneration Devices market in the U.S. is estimated at US$2.2 Billion in the year 2021. The country currently accounts for a 30.45% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$1.8 Billion in the year 2026 trailing a CAGR of 13% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.7% and 8.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR while Rest of European market (as defined in the study) will reach US$2 Billion by the end of the analysis period. Increasing incidence of neurological diseases and expanding geriatric population, increasing spending on healthcare sector, positive reimbursement framework and presence of several leading industry players are fueling growth in the North America region. Asia-Pacific is poised to grow at a robust pace, driven by sizeable patient pool, favorable healthcare initiatives and high unmet healthcare needs. The Asia-Pacific market is expected to gain from notable surge in aging population, increasing awareness regarding neurological disorders, and rising incidence of cancer and osteoporosis. Select Competitors (Total 61 Featured)

Read the full report: https://www.reportlinker.com/p05957490/?utm_source=GNW

CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Impact of Covid-19 and a Looming Global Recession 2020 Marked as a Year of Disruption & Transformation EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for 2019 to 2022 Global Nerve Repair & Regeneration Market Buckles under COVID- 19 Strain Covid-19 Patients in Prone Position Suffering Nerve Damage Bodes Well for Market Growth Nerve Repair and Regeneration Market Set for a Robust Growth Neurostimulation & Neuromodulation Devices Hold Commanding Slot in Nerve Repair & Regeneration Market Biomaterials to Exhibit Rapid Growth Nerve Repair and Regeneration Market by Application US and Europe Dominate the Market Asia-Pacific and other Emerging Regions Display Impressive Growth Potential Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS High Incidence of Neurological Disorders: A Key Market Driver EXHIBIT 2: Annual Incidence of Adult-Onset Neurologic Disorders in the US Effects of COVID-19 on the Nervous System Sheds Focus on Neuromodulation Applications Increasing Cases of Peripheral Nerve Injuries Drive the Nerve Repair and Regeneration Market Growing Number of Vehicular Accidents Drive the Peripheral Nerve injuries Repair Market Rising Geriatric Population and Subsequent Growth in Prevalence of Neurological Disorders EXHIBIT 3: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Growing Incidence of Neurodegenerative Diseases Propels the Market for Deep Brain Stimulation Devices EXHIBIT 4: Global Alzheimers Prevalence by Age Group EXHIBIT 5: Diagnosed Prevalence Cases of Parkinson?s Disease Across Select Countries EXHIBIT 6: Global DBS Market by Leading Player (2020E): Market Share Breakdown of Revenues for Medtronic, Boston Scientific, and Abbott Select Available Deep Brain Stimulation Devices Available in the Market Intensified Research Activity Across Various Neural Disciplines Induces Additional Optimism Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration Increasing Cases of Epilepsy Drives the Demand for Vagus Nerve Stimulation Devices EXHIBIT 7: Epilepsy Incidence by Type (2019): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy EXHIBIT 8: Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy Spinal Cord Injuries Propel the Demand for Spinal Cord Stimulation Devices Recent Developments in Spinal Cord Injury Treatment Biomaterials (Nerve Conduits and Nerve Wraps) to Witness Rapid Growth New Biomaterials Pave the Way for Innovative Neurodegeneration Therapies Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Innovative Nerve Conduits from Stryker TENS (Transcutaneous electrical nerve stimulation devices) Market Witnesses Rapid Growth Non-Invasiveness of TMS (Transcranial Magnetic Stimulation) Propelling the adoption of TMS devices Nerve Grafts for Bridging Larger Nerve Gaps Role of Nerve Grafting in Treatment of Peripheral Nerve Injuries FDA-approved Nerve Tubes for Peripheral Nerve Repair

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Neurostimulation & Neuromodulation Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Biomaterials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Neurostimulation & Neuromodulation Surgeries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Neurorrhaphy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Nerve Grafting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES Table 28: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 29: USA Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 31: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 34: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

CANADA Table 37: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 39: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 40: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 41: Canada Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 43: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

JAPAN Table 46: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 48: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 49: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Japan Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 52: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 54: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

CHINA Table 55: China Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 56: China Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 57: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 58: China Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 59: China Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 61: China Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 62: China Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 63: China 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

EUROPE Table 64: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 65: Europe Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 66: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 67: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 70: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 71: Europe Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

FRANCE Table 76: France Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 77: France Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 78: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 79: France Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 80: France Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 81: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 82: France Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 84: France 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

GERMANY Table 85: Germany Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 86: Germany Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 87: Germany 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 88: Germany Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

View post:
Global Nerve Repair and Regeneration Devices Market to Reach $11. 8 Billion by 2026 - GlobeNewswire

Sir, Andrew Mullen (Letters, July 21st) is in good company when he raises the issue of the legitimacy of the creation story.

Science has made huge steps forward in the last 50 years, with the field of molecular genetics emerging from the realization that DNA and RNA (ribonucleic acid) constitute the genetic material in all living things.

The Human Genome Project, the worlds largest collaborative biology research project, completed in April 2003, was headed up by Francis Collins.

His previous research projects involved the discovery of the genes that cause cystic fibrosis, cancer tumour growth and Huntington chorea, a neurological disease.

As a scientist, he has this to say on the creation story: The God of the Bible is also the God of the genome. He can be worshipped in a cathedral or in the laboratory. His creation is majestic, awesome, intricate, and beautiful

Progressive science, it seems, favours worship over mockery and ridicule. Yours, etc,

SEAMUS OCALLAGHAN,

Carlow.

Sir, Andrew Mullens letter is valid up to a point. He has the right to his own opinion regarding creation. Edwin Poots, et al, should not be ridiculed. If they want to believe the Genesis story as literal and historical, let them. They are harmless as long as they do not impose their ideas on others. Science and modern Christian theology agree that creation began around 13.7 billion years ago and what we observe now is the result of evolution. There is no point in arguing with creationists as they already know who God is. Yours, etc,

PAT COURTNEY,

Kilmyshall,

Wexford.

A chara, In claiming that a culture of intolerance ridicules and mocks normal Christian beliefs, Andrew Mullen seeks to defend Edwin Pootss creationist viewpoint.

As an atheist, I have no quarrel with any individuals beliefs but the record of politicians dictating what is acceptable through legislation is fairly dismal.

Not so long ago, the religious beliefs of certain politicians ensured that people in same-sex relationships or who got pregnant without being married were, at the very least, culturally unacceptable and, at worst, liable to prosecution.

Belief in mindless tradition and irrational superstition is grand as long as it is kept private. Is mise,

GREG SCANLON,

Shannon,

Co Clare.

Read more:
In the beginning science and faith - The Irish Times

The banks of the artificial water reservoirs in Tikal, a major city of the ancient Maya world in what is now northern Guatemala, were primarily fringed with trees and wild vegetation, according to an analysis of ancient environmental DNA.

Tikal was a flourishing seat of power, religion and trade for Mesoamerica in what is now northern Guatemala; at its zenith around 830 CE the population reached somewhere between 40,000 and 62,000 inhabitants. Image credit: David Lentz.

Almost all of Tikals city center was paved. That would get pretty hot during the dry season, said Professor David Lentz, a paleoethnobotanist in the Department of Biological Sciences at the University of Cincinnati.

So it would make sense that they would have places that were nice and cool right along the reservoir.

It must have been beautiful to look at with the water and trees and a welcome place for the kings and their families to go.

Previously, scientists learned about the crops and wild plants that grew in Tikal by studying ancient pollen or charcoal.

For the new study, Professor Lentz and his colleagues developed a novel system to analyze ancient plant DNA in the sediment of Tikals Temple and Palace water reservoirs.

They were able to amplify small strands of DNA from chloroplasts, the plant structures where photosynthesis takes place.

Then they could match the ancient Tikal samples with the DNA of known plant species in much the same way scientists amplify ribosomal DNA to identify species of bacteria.

The analysis was quite challenging because we were the first to do this, said Professor Alison Weiss, a microbiologist in the Department of Molecular Genetics, Biochemistry and Microbiology at the University of Cincinnati.

Bacterial ribosomal DNA has a database. There was no database for this. We had to take sequences one by one and search the general database to find the best match.

The team identified more than 30 species of trees (like cabbage bark and ramn), grasses, vines and flowering plants that lived along the banks of Tikals reservoirs.

Ramn is a dominant rainforest species in Guatemala, Professor Lentz said.

Why you would find ramn around the reservoir is a curiosity. The answer is they left this forest intact.

Tikal has a harsh climate. Its pretty tough to survive when you dont get rain for five months of the year. This reservoir would have been the font of their lives. So they sometimes would protect these places by not cutting down the trees and preserving a sacred grove.

Among dozens of plants native to the region, the authors found evidence of wild onion, fig, wild cherry and two types of grasses.

Grass seeds might have been introduced to the reservoir by visiting waterfowl. Grass would have proliferated at the edges of the reservoirs during dry seasons and droughts, Professor Lentz said.

Tikal had a series of devastating droughts. As the water levels dropped, they saw blue green algae blooms, which produce toxic substances.

The droughts were great for the grass but not so much for the forest plants that lived along the reservoirs banks.

Were these wild areas the equivalent of a park? I think they were. I dont know how public they would have been, he added.

This was a sacred area of the city surrounded by temples and palaces. I dont know if the commoners would have been that welcome.

A paper on the findings was published in the journal Scientific Reports.

_____

D.L. Lentz et al. 2021. Environmental DNA reveals arboreal cityscapes at the Ancient Maya Center of Tikal. Sci Rep 11, 12725; doi: 10.1038/s41598-021-91620-6

Link:
Ancient Maya Maintained Native Tropical Forest Plants around Their Water Reservoirs | Archaeology - Sci-News.com

The RDM Positive Impact Foundation is funding an ambitious $1.25 million research project at the UC Davis MIND Institute to study SYNGAP1. The rare genetic condition causes seizures (epilepsy), intellectual disability and developmental delays. It is also highly associated with autism; about half of all SYNGAP1 patients have an autism diagnosis.

A staff member conducts research in the Segal Lab.

Ron Mittelstaedt and his wife, Darin, who live in El Dorado Hills, run the foundation. Hes the executive chairman of Waste Connections, a solid waste and recycling company with 20,000 employees in North America, and his family operates Toogood Estate Winery in Somerset. The Mittelstaedts have donated millions of dollars to organizations that help children over the past 15 years.

This time, its personal.

About three and-a-half years ago, Ron Mittelstaedts best friend died, leaving behind three sons and their families. Ive become sort of a surrogate dad, and now a surrogate grandfather, explained Mittelstaedt. One of those grandsons was diagnosed with a SYNGAP1 mutation a year and-a-half ago. With the familys support, Mittelstaedt is providing meaningful funding to the MIND Institute to advance research about the syndrome.

The reality is, like many rare conditions, there arent a lot of great options. So, were trying to find potentially life-changing treatment that hopefully may impact the lives of people with SYNGAP1, he said.

Mittelstaedt was previously on the MIND Institutes inaugural National Council of Visitors (then called the MIND Institute Advisory Council), and funded a successful research project that developed a blood test for Tourette syndrome.

A staff member in the Silverman lab conducts behavioral neuroscience research.

We are grateful to the Mittelstaedts for their generosity, said MIND Institute Director Leonard Abbeduto. As a collaborative hub for preclinical and clinical research on neurodevelopmental disability, the MIND Institute is uniquely suited to build on past successes and tackle the complexities of SYNGAP1 to provide help for families.

The funding also supports UC Davis' $2 billion fundraising campaign, Expect Greater: From UC Davis, For the World, the largest philanthropic endeavor in university history. Together, donors and UC Davis are advancing work to prepare future leaders, sustain healthier communities, and bring innovative solutions to today's most urgent challenges.

SYNGAP1-related non-syndromic intellectual disability is a rare neurodevelopmental condition caused by a variation in one gene. The gene, SYNGAP1, contains instructions for making a protein (SynGAP). This protein is located at the junctions between nerve cells, called synapses, and helps regulate changes important for memory and learning. The protein also helps regulate communication between neurons.

When the variation is present, the SYNGAP1 protein in cells is reduced which causes an increase in the excitability in the synapses. This makes it difficult for neurons to communicate and increases the likelihood of seizure events. This can lead to a variety of symptoms:

Jill Silverman

SYNGAP1 syndrome affects 1-4 out of 10,000 people. The first patient was identified in 2009.

The MIND Institutes interventional genetics team includes faculty who specialize in multiple research areas.

Ron Mittelstaedt

Each of us is a world expert in our particular discipline, so bringing us all together means the chances of success are much more likely, said Jill Silverman, associate professor in the Department of Psychiatry and Behavioral Sciences and an internationally recognized expert in the use of rodent models for therapeutic development. Silvermans Lab is known for its expertise in behavioral neuroscience research.

In addition to Silverman, the SYNGAP1 team includes three other MIND Institute faculty members:

The sum of the group is going to be much greater than anything we could have done alone, said Fink, whose lab focuses on therapeutic development for neurodevelopmental conditions and neurodegenerative diseases. The fact that the foundation has funded us as a team, across multiple centers and programs is really unique. This funding brings us all together for an important project.

Kyle Fink in his lab, which focuses on therapeutic development for neurodevelopmental conditions and neurodegenerative diseases.

The researchers will work on parallel tracks, each contributing a piece of the puzzle.

Silverman will conduct specialized behavioral tests on mouse models of SYNGAP1, using tools with corresponding metrics in humans, such as EEGs (a type of brain scan) to determine clinically relevant outcomes.

Nord and Fink will create a new mouse model that contains the mutated human SYNGAP1 gene, while Segal and Fink will create new molecular therapies to counter that mutated gene. Theyll also figure out how to deliver those therapies to the brain.

Were not just trying to treat the symptoms of the disease with a drug, explained Segal, whose lab specializes in molecular analysis. We are trying to change the underlying genetic condition, and our particular approach is to do that in a way that does not change the DNA sequence. We use tools to change the gene expression instead, which we think will make safer therapies. Its really a state-of-the-art approach. Its molecular therapy.

David Segal working in his lab, which specializes in molecular analysis.

The collaborative approach, often called team science, coupled with the RDM Positive Impact Foundations support, allows for an ambitious, fast-tracked research program. The $1.25 million frees the researchers from the need to apply for multiple federal grants and enables them to focus immediately on SYNGAP1.

The team excels in whats often called bench to bedside research, translating results from the lab directly into therapies for patients.

We see these patients, we meet with them, were on Zoom calls with them and I want to find something that works for them. I want to change their lives. Thats what Im driven by, Silverman said.

Silverman, Fink and Segal have had previous success with their work on another rare genetic condition, Angelman syndrome, which causes developmental delay, speech and balance challenges and intellectual disability.

David Segal

Their labs helped to create and characterize the first rat model of Angelman syndrome last year. The Segal lab also created a protein therapeutic that could increase the level of the affected gene in mouse models of Angelman syndrome, a major discovery.

All three labs are still working on a wide range of therapeutics for Angelman, including molecular therapies delivered with viruses or stem cells and novel small molecule compounds.

Ron Mittelstaedt is hoping for another success story, this time with SYNGAP1, but hes also realistic about the research process.

We are all very aware that going down this path doesnt guarantee anything except the ability to get up to bat, and we could get a hit or strike out. But doing nothing guarantees you dont get a hit, so its important for us to take action, and were hopeful well hit a home run.

UC Davis researchers get $3 million FAST grant to find treatment for Angelman syndrome

The UC Davis MIND Institute in Sacramento, Calif. was founded in 1998 as a unique interdisciplinary research center where families, community leaders, researchers, clinicians and volunteers work together toward a common goal: researching causes, treatments and potential prevention of neurodevelopmental disabilities. The institute has major research efforts in autism, fragile X syndrome, chromosome 22q11.2 deletion syndrome, attention-deficit/hyperactivity disorder (ADHD) and Down syndrome. More information about the institute and its Distinguished Lecturer Series, including previous presentations in this series, is available on the Web at mindinstitute.ucdavis.edu.

See original here:
Local foundation awards $1.25 million to MIND Institute to study rare genetic condition - UC Davis Health

Inventum Genetics GmbH and Universitt Marburg agree on a collaboration

The project company of Xlife Sciences AG Inventum Genetics GmbH has signed a collaboration agreement with the Philipps-University of Marburg. In this way, Inventum Genetics has the exclusive opportunity to develop new therapeutic targets using high-quality genetic data.

ZUERICH, SWITZERLAND / ACCESSWIRE / June 22, 2021 / The cooperation between Inventum Genetics and the University of Marburg is a long-term agreement. In a first projects, new therapeutic targets and biomarkers for oncological, neurodegenerative and age-related diseases are be identified using the latest genetic and molecular biological processes. Oliver R. Baumann, CEO der Xlife Sciences, is delighted with the additional prospects for drug development: "All common diseases, like the majority of all oncological, neurodegenerative and age-associated diseases, are multifactorial in cause, not just caused by a singular genetic defect. Rather, multifactorial diseases are characterized by the fact that they are based on (exogenous) environmental factors and (endogenous) genetic risk factors. In this particular project with the University of Marburg, cellular disease mechanisms of multifactorial diseases are to be elucidated. For this purpose, cells are stimulated with exogenous risk factors. It will then be examined how the cells react to it depending on their genetic makeup."

The agreement with the Philipps-University of Marburg gives the university the right to pursue the results achieved in its own research and to industrialize them, provided Inventum Genetics does not use the results itself. In this case, Inventum Genetics would benefit from the royalties generated by the university.

About the Philipps-University MarburgThe Institute for Human Genetics at the Faculty of Medicine at the Philipps-University of Marburg, under the leadership of Professor Dr. Johannes Schumacher is well recognized by high-ranking publications in research in the field of human genetics. The institute operates a molecular laboratory with high quality equipment and is therefore able to deal with complex issues in the context of molecular genetic research.

Story continues

About Inventum Genetics GmbHInventum Genetics GmbH is a subsidiary of Xlife Sciences AG, which is active in research, development, manufacturing and the sale of medical and biotechnological products, especially in the field of genetics. For more information, please visit: https://www.inventumgenetics.com

About Xlife Sciences AGXlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: http://www.xlifesciences.ch

For media inquiries:Dennis Lennartz, Head Investor Relations, Xlife Sciences AG, Tel. +41 44 385 84 60, dennis.lennartz@xlifesciences.ch

For scientific inquiries:Dr. Frank Plger, Chief Scientific Officer, Xlife Sciences AG, Tel. +41 44 385 84 62,frank.ploeger@xlifesciences.ch

SOURCE: Xlife Sciences AG

View source version on accesswire.com: https://www.accesswire.com/652623/Xlife-Sciences-AG-Collaboration-with-the-University-of-Marburg

More here:
Xlife Sciences AG: Collaboration with the University of Marburg - Yahoo Finance

'If genetic testing is done at the appropriate stage, some diseases can be prevented, cured or managed better.'

The Indian diagnostics industry has been rapidly evolving over the years and its emerged to be a key component of the healthcare segment. The arrival of Covid-19 pandemic pushed the healthcare industry to the sting worldwide by throwing many challenges, and therefore the diagnostic sector too witnessed a large transition during this phase. Whether its about keeping pace with the concept of telemedicine or addressing the change within the consumer psyche, the diagnostic sector has been facing different challenges with the increase of covid cases. As COVID-19 has spread, Indias diagnostic sector has been battling the virus at the forefront. In conversation with Financial Express Neeraj Gupta, Founder and CEO of Genes2me shared his experience and threw light on the challenges, learnings, and therefore the road ahead for the diagnostic businesses in India. Excerpts:

How has the diagnostic sector evolved since the arrival of Covid-19? Being an industry leader, what were some initial challenges you faced?Previously, the molecular diagnostic sector was not harnessed. We have seen that pandemic pushed the healthcare industry to the edge, but Indias diagnostic sector rose to meet the challenges. As COVID-19 has spread, Indias diagnostic sector has been combating the virus at the forefront. Initially, the Indian health care system was not fully prepared for such a massive crisis like COVID-19. We faced challenges regarding imports for raw materials and logistics due to global supply chain disruptions. This is also one of the reasons why we decided to use our expertise in molecular diagnostics and expand the portfolio into IVD manufacturing.

How has Genes2me come to the forefront during the pandemic? Tell us about your journey of delivering 40 Million covid test kits in India to date.

We take pride in the fact that Genes2Me has been working at the front line from the very first day of the pandemic. We developed several IVD kits, including Real-Time PCR Kits, VTM Kit, RNA Extraction Kits, NGS Kits and multiplexed genotyping assays for COVID-19 detection in a quick turnaround time.

Our ViralDtect-II Real-Time PCR Kit for COVID-19 has been a real turning point. It was the first Made in India Real-Time PCR Kit with comprehensive coverage of three genes that are specific to SARS-COV-2.

Also, there have been reports of new strains of SARS-COV-2 being detected. Genes2Me has developed a Unique Mutation Classifier assay that can rapidly differentiate 40 variants between 16 SARS-CoV-2 strains. This can help in the quick genetic screening of large sections of the population.

Genes2Me have been working tirelessly and have delivered more than 40 million COVID-19 testing kits to date. Also, to meet the sudden demand surge of the second Covid wave, we ramped our manufacturing facility from 9million per month to 6 million per week. In fact, during this time, Genes2Me contributed over 20% of the entire Indian testing needs for RT-PCR.

From where the idea of stepping into manufacturing IVD kits came under the Make in India initiative? What have been the challenges and opportunities?

When the pandemic hit us, not many diagnostic labs had the necessary infrastructure or accreditations to offer Covid testing facilities. As the pandemic gathered force, there was not only demand for faster testing but also testing in much higher volumes. The response to that struggle was the idea behind IVD kits under the Make in India initiative.The Indian government has taken progressive steps to boost the capacities of the domestic IVD sector. Genes2Me is also working to collaborate with the government and prestigious medical institutes to offer services on the innovative classifier panel of SARS-COV-2. In this manner, we can all be better prepared to face the challenges posed by this virus frequently changing genetic makeup.

What changes should diagnostic companies bring to fight the pandemic and meet the current market demand?

Post Covid-19, we have seen the entry of many companies into the Molecular Diagnostics Testing and Kit Manufacturing segment. Unfortunately, not many companies have been able to deliver quality genetic solutions in a fast turnaround time. This is evident from the fact that around 10-15 players used to compete in the Tender queries of IVD products till last year. But now, only 4-5 bidders are participating in the Tender queries as most of the companies have failed to satisfy customer expectations of Quality Product.

If you want to build a sustainable diagnostic company, you should maintain Quality Manufacturing and Testing Standards. Genes2Me has responded by building capacities and training faster to keep up with the surge without compromising the sensitivity of Genetic Solutions.

What have been some recent developments and future plans of Genes2me?

Genes2Me is vigorously working to leverage the large installed base of molecular testing platforms across the globe. With the help of our expertise and access to advanced technologies, we have developed several assays for Infectious diseases, Oncology and Reproductive Health in India. In the past, most of these test panels were import-dependent from other countries.

In addition, under the Make in India initiative, we are working to develop diverse nucleic acid research and diagnostics solutions along with NGS reagents for genome sequencing. Again, these solutions were dependent on import from different nations.

Genes2Me has also ramped up Covid-19 testing facilities by installing more infrastructure, hiring manpower and training them meticulously to ensure smooth functioning. Our advanced high throughput Real-Time PCR testing Lab at Gurgaon, Haryana, has an unmatched capacity to perform 8K-10K tests per day.

How do you see the future of Genetic Diagnostics in India?

India has a population of more than 1.26 billion people, with 26 million births occurring every year. This means that the burden of a genetic disease is very high. With the help of genetic diagnostics, many diseases can be predicted with great accuracy. If genetic testing is done at the appropriate stage, some diseases can be prevented, cured or managed better.

Genetics diagnostics in India is on the verge of transformation. There has been widespread awareness and recognition of the increasing incidence of congenital and hereditary genetic diseases in urban India. More and more people are seeking genetic testing and counselling services. Genetic diagnostic in India will evolve from a niche speciality to a wide scope of applications for complex diseases and personal use.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know markets Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Read the original post:
Genetics diagnostics in India is on the verge of transformation: Neeraj Gupta, Founder and CEO of Genes2me - The Financial Express

Cancer treatments are improving as scientists are finding ways to develop new techniques and treatments. One of which is precision medicine, where they have focused on improving patients health using personalized solutions.

RELATED: Oxfords Genomics Pushing the Boundaries of Personalized Medicine

Precision medicine, in the simplest definition, is the way a patient is treated, diagnosed, or prevent disease by checking his/her genetics, environment, or lifestyle.

This type of treatment is related to pharmacogenomics. Where pharmacogenomics is the study of how a persons gene affects his/her response to a drug, it is used to treat a person through effective and safe medication tailored to their genes.

Precision medicine is now commonly used on patients treated with pancreatic cancer, lung cancer, melanoma/skin cancer, and colon cancer. It is also used to detect and treat HIV and cystic fibrosis.

Slowly, it is also seen in treatments for heart diseases, Alzheimers disease, rheumatoid arthritis, and multiple sclerosis.

In cancer patients, most medical facilities treat every patient the same way. However, studies suggest that not everyone responds to treatments the same way. One persons body may react differently with medicines as compared to another person.

Genetics plays a role in treating tumors, and precision medicine promise to tailor treatments based on a persons genes. It is seeing how a tumor would react to certain treatments that may work for other people.

Precision medicine can be used in the prevention and prediction of disease and management and treatment. Here are some examples of how it is used to treat, prevent, or treat people in a practical setting.

Checking your familys history of diseases and illnesses can somehow determine what you are capable of acquiring. If a family member has a history of cancer, heart diseases, diabetes, high blood pressure, or other chronic diseases, there is a high chance of you getting it.

With this data and information, a doctor can create treatment plans to prevent these from happening to you.

For example, when the doctor finds out that any of your family members had breast cancer, then the chances of you having it is likely. The doctor will then decide for you to have regular mammograms to check for any signs.

Newborns (usually right after theyre conceived) are screened where blood samples are taken. This test will check if they have any pre-existing conditions acquired from their parents, check hearing capabilities or heart defects, among others.

This way, the baby will be treated accordingly if any crucial or life-threatening conditions are seen.

For example, the newborn screening shows Baby Mary has severe combined immunodeficiency (SCID), she will receive a bone marrow transplant immediately to battle her condition. SCID is life-threatening to babies since its responsible for fighting off infections.

Personal trackers such as smartwatches or other mobile devices that check on your health can be lifesavers and be tools for precision medicine.

For example, a person is notified by his smart device that he is experiencing abnormal heart rates even if he has no family history of any heart condition. He then goes to see a doctor because of this and has been diagnosed with atrial fibrillation. This device could have saved his life because that condition can lead to a stroke. Now, he can treat his condition before it worsens.

Genomic sequencing can be used to control and track-out infectious diseases. Similar to whats been used to track COVID-19, this approach shows a DNA of a germ or virus where scientists have the opportunity to learn more about it and find a treatment a cure for it.

An example of this is the COVID-19, where scientists were able to extract samples from those infected with the virus and learn about it and find vaccines and cures for it, which is now slowly happening to us.

As a treatment, tumor profiling is genetic testing of a tumor. It is a way for doctors to choose which kind of treatment they would use for a condition. They would know from this process if cancer will return or would need radiation or chemotherapy.

For example, Jennys breast cancer returned and is diagnosed again. But her tumor profiling reveals she has triple-negative breast cancer. Her approach to this, along with her doctors, is a more aggressive one, including chemotherapy, radiation, and mastectomy.

RELATED: FDA Approves GSKs Checkpoint Inhibitor Jemperli for Endometrial Cancer

As mentioned above, pharmacogenomics studies how a person reacts to a certain treatment based on their genes. Doctors using this treatment can gauge if a certain medicine can be effective or not based on a patients history. They can also determine if the patient will experience any serious side effects.

For example, John needs to undergo Fluorouracil (5-FU), which is a type of chemotherapy. But if John has a low level of an enzyme called dihydropyrimidine dehydrogenase (DPD), which helps metabolize fluorouracil in the body, the doctors would need to check on him using pharmacogenomics. If he has a low dose of fluorouracil, an oncologist will decrease the dosage in the chemotherapy to prevent any serious side effects.

With these examples revealed, some facilities and companies provide precision medicine to improve the living conditions of patients treated with different diseases.

ExactCure is a French start-up that combines artificial intelligence with precision medicine to create flawless software for the use of drugs to be used by patients depending on their kidney status, genotype, gender, or age.

Patients use this service by inputting their data, and ExactCure will give the necessary medications based on the information provided.

Tepthera is a Swiss start-up that focuses on cancer immunotherapy, infectious and auto-immune diseases.

Their focus concerning precision medicine is on identifying T cell antigens for better and personalized therapies and treatment.

Caris Life Sciences is a molecular science company that focuses on precision medicine in oncology. They are working on the development of innovative therapeutics and advance potential treatments for cancer in the clinic.

They develop profiling assays for oncology that scan DNA, RNA and proteins to reveal a molecular blueprint to help physicians determine the best course of treatment for cancer patients.

Precigen is a Maryland-based company that is advancing its UltraCAR-T cell therapy approach to treating cancer.

They are now developing next-generation gene and cell therapies that can change the treatment paradigm in immuno-oncology, autoimmune disorders and infectious diseases.

There are numerous ways to treat diseases and medical conditions with the use of precision medicine. Scientists are continually finding out ways to improve patients lives by using their traits.

Read more:
Precision Medicine: Improving Health With Personalized Solutions - BioSpace

Across metro Portland, 22 students from 10 public and private high schools have won the coveted $2,500 National Merit scholarships given to students who show exceptional promise.

Half of those 2021 winners attended just two high schools: Sunset and Westview, both in the Beaverton School District.

Three other high schools had two winners each: the private Jesuit and Catlin Gabel schools and Lake Oswego High.

Winners of the $2,500 scholarships are judged the best of the best among National Merit Scholars, with what the scholarship organization says are the strongest combination of accomplishments, skills and potential for success in college. Panels of high school counselors and college admission officers pick them based on grades, difficulty of courses taken, standardized test scores, an essay and recommendations from a teacher and their high school.

Normally, as happened this year, National Merit officials limit that to 26 students across Oregon. In addition to the 22 winners from the Portland area, students in Ashland, Bend, Eugene and Silverton also made the elite achiever list.

The National Merit Corporation provides extremely limited information about winners, and The Oregonian/OregonLive found most of this information through independent research. Some school officials, including those at Sunset High, did not respond to requests for information about their winning students.

Here are the winning Portland-area students with additional information as available:

Catlin Gabel

Sophie Kruse, senior class president at Catlin Gabel, is headed to Columbia University to study engineering.

Sophia Kruse

She was a state leader in the Students Demand Action office, which mobilizes and educates voters about gun violence, and was elected senior class president at Catlin Gabel. She competed for four years as a member of Lincoln Highs varsity lacrosse team and was named player of the year in Portland Public Schools her senior year. She competed on Catlins cross country team and its soccer team, which won two state championships. She worked on her schools environmental action team all four years of high school. She will attend Columbia University, where she plans to study engineering.

Tiffany Toh, a standout in debat and robotics, is headed to Yale University.

Tiffany Toh

During high school, she was interested in music and debate and was known for being extremely energetic, according to the Catlin website. She served as a three-year member and eventual co-leader of the winning robotics team, The Flaming Chickens. She was a member of the varsity swim team and served as a school ambassador. As a senior, she was named one of 10 Deans List students among 90,000 who competed in events leading to the international high school robotics competition. She is headed to Yale University and told National Merit officials she is likely to major in biomedical engineering.

Krishna Home school

Gopal Goel, who placed fourth in the nation's oldest and most prestigious math and science competition for high school seniors, is headed to MIT to study math and physics.

Gopal Goel

He won $100,000 the nations oldest and most prestigious science and math competition for high school seniors for math research that made connections between two subjects regarding randomness and probability. He told contest organizers he hopes his work will aid in the search for the true nature of quantum gravity, more commonly known as the theory of everything. He can solve a Rubiks cube even while blindfolded. He won a silver medal at the 2020 International Math Olympiad. He mentored students on the U.S. Physics Olympiad team. He is headed to the Massachusetts Institute of Technology, better known as MIT, and plans to study math and physics.

Jesuit

Eliza Daigle, who reveled in lacrosse, science and volunteerism during high school, is headed to Whitman College, where she plans to study biochemistry and related fields.

Eliza Daigle

She earned class academic achievement awards in science and Spanish. She served as co-captain of the womens varsity lacrosse team, which won its first state championship in 2019 and won again this year. She took part in Oregon Health & Science Universitys partnership in scientific inquiry program, which introduces high school students to the scientific process and laboratory research. In turn, she served as a co-leader of Jesuits junior scientists program, which aims to encourage a love of science through fun experiments that develop problem solving and critical thinking skills. She volunteered at Trinity Episcopal Cathedral and contributed more than 100 hours of service to Good Samaritan Medical Center. She is headed to Whitman College, where she will play lacrosse and plans to major in biochemistry, biophysics and molecular biology.

Passionate about computer science, problem solving and research, Marissa Kuo is headed to Santa Clara University to study computer science and engineering.

Marissa Kuo

She received the outstanding applied chemistry award from the Portland chapter of the American Chemical Society at the Northwest Science Fair for her research on green chemistry methods for degrading neurotoxic herbicides. She interned at Portland State University in a computer science lab where she studied computer algorithms for night vision. She helped lead her schools Asian Student Union and research club. She competed on the Jesuit swim team. Passionate about computer science, problem solving, and research, she is headed to Santa Clara University to study computer science and engineering.

Lakeridge

Roselyn Dai

She volunteered as a peer intervention specialist at the Portland-based teen crisis hotline YouthLine and was honored by the Oregon Chinese Coalition for her volunteerism. She also volunteered at two local medical centers and was a multi-year member of her schools speech and debate team. She told National Merit officials she is likely to study medicine.

Lake Oswego

Jackie Booth, who played varsity tennis and taught younger students math for three years, is headed to the University of Southern California.

Jaqueline Jackie Booth

She competed all four years on the varsity tennis team and volunteered regularly at Portland Rescue Mission and other community organizations. She co-led the schools fellowship club and worked as a math instructor at Mathnasium Learning Center since her sophomore year. She is headed to the University of Southern California, where she plans to major in philosophy, politics and law.

George Danzelaud, a poet, violin player, singer-songwriter and varsity sprinter, is headed to the University of Southern California to study business and computer science.Randal Leitch Photography

George Danzelaud

A varsity sprinter who loves both science and the arts, he was elected president of his senior class. He performed a virtual concert with his brother to raise money for the Oregon Humane Society in the wake of last summers deadly wildfires. He performed solo violin at Carnegie Hall, won a gold award for his poetry and is a self-taught guitarist and singer who published three songs on iTunes and Spotify. He is headed to the University of Southern California and plans to double major in computer science and business.

Oregon Episcopal School

Lila Schweinfurth

She was the state winner of U.S. Stockholm Junior Water Prize. Her research on predicting harmful algal blooms to improve water quality also put her among the five Oregon students named semifinalists in the nations oldest and most prestigious math and science compeitions for high school seniors. She plays violin and plans to study science and prepare for a career involving research, according to National Merit officials.

Sunset

Anika Gupta is passionate about the real-world applications of science and technology and has deeply researched aquaponics in pursuit of sustainably growing food. She will attend the University of Southern California, where she plans to double major in business and computer science.

Anika Gupta

Anika Gupta is passionate about equity and real-world applicability of science and technology. Four years ago, she started a classroom aquaponics project that shes since grown into a bioengineering syllabus used by more than 700 student researchers. Shes working alongside the NASA Ames Research Center to learn to grow food sustainably. Anika also co-founded Project Portland Carry, a nonprofit to support students during COVID through educational helplines and accessible lunch delivery. As president of the Sunset speech and debate club, Anika rebuilt her club amid what she called existential challenges and led Sunset to a state championship victory this spring. She personally was named Oregons top extemporaneous speaker. She is also a recipient of the prestigious Coca-Cola Scholarship. She is headed to the University of Southern California, where she plans to study business and computer science.

Amuthan Amu Ilavarasan

He won a scholarship for winning an art competition. He designs and sells t-shirts. He told National Merit officials he was likely to study environmental science.

Eric Kim conducted two years of research on bioinformatics at Oregon Health & Science University, plays clarinet and is a competitive Taekwondo sparring athlete. He is headed to Columbia University.

Eric Kim

He founded and led the Sunset Science Ambassadors program that matches high school science scholars with fifth-graders to mentor them through hands-on science projects. He is one of five Oregon students named a Regeneron Scholar for his biology research as part of the nations oldest and most prestigious science and math competitions for high school seniors. A longtime volunteer for hard-of-hearing individuals, he designed see-through face masks to aid their communication during the pandemic and helped people all over the country get materials and instructions needed to make them. He conducted two years of research on bioinformatics at Oregon Health & Science University, plays clarinet and is a competitive Taekwondo sparring athlete. He is headed to Columbia University.

Kevin Seog led Oregon's top team in the Tests of Engineering Aptitude, Mathematics, and Science contest in 2020 and 2021. He is headed to Berkeley, where he plans to double major in business and computer science.

Kevin Minjay Seog

He co-led Oregons top team in the Tests of Engineering Aptitude, Mathematics, and Science contest this spring and last. He provided illustrations for a college-level economics book focusing on risk and insurance. He plays piano and guitar. He is headed to the University of California, Berkeley, where he intends to double major in computer science and business.

Stan Wing founded and led a nonprofit dedicated to providing free debate opportunities to middle schoolers across Oregon. He is headed to New York Universitys Stern School of Business to study business with concentrations in finance and econometrics.

Stanley Wang

During high school, he honed his skills as a landscape and portrait photographer. He competed as a member of Sunsets golf team. His primary extracurricular involvement during high school was with Health Occupations Students of America, an organization that holds state and international business competitions and conferences for high school students and its health careers counterpart. He helped found and served as president of the Oregon Middle School Speech and Debate League, a nonprofit dedicated to providing free debate opportunities to middle schoolers across Oregon. He is headed to New York Universitys Stern School of Business to study business with concentrations in finance and econometrics.

Lele Yang was a frequent volunteer during high school, including leading a group that taught computer science lessons to middle and high school students. She is headed to Penn State University, where she will take part in an accelerated premedical and medical program.

Lele Zixin Yang

Yang was president of Tech4Girls, in which she taught computer science lessons to middle and high school students. She gathered resources and grants for the program and also trained student teachers to help with the classes. She is an artist and a competitive fencer. Yang will enter the accelerated premedical-medical program at Penn State University in the fall.

Tualatin

Aven Sadighi, who competed in sports and business, is headed to Oregon State Universitys Honors College to study computer science with a focus on artificial intelligence.

Aven Sadighi

The Tualatin High valedictorian volunteered for three years tutoring fellow students. He competed and medaled at the 2020 Health Occupations Students of America state conference. He spent three years as a member of Pack Leaders, the student group that aids incoming freshmen in navigating their first year of high school. He competed freshman year in cross country, baseball and track and spent many hours volunteering in the community as a member of the National Honors Society. Hes headed to Oregon State Universitys Honors College to study computer science with a focus on artificial intelligence.

West Linn

Gillian Herbert

Herbert plans to study public policy in college, National Merit officials indicated.

Westview

Sangana Ilango

Ilango won a Congressional App Challenge for her mobile phone application, Spoiler Alert!, that helps consumers determine if food and medications are safe to use. She founded a club called CodeHERS to help encourage elementary girls to try computer coding. She worked as a research assistant at Oregon Health & Science University in summer 2019, interned at Mentor Graphics in summer 2020 and is interning with the product management team at Oregon Sesame this summer. Shes headed to the University of Southern California and will major in computer science.

Adam Jones

He conducted genomic research in Portland State Universitys Extreme Virus Lab. He competed at least one year for his high schools baseball, track and soccer teams. He is likely to study engineering in college, according to National Merit officials.

Pranav Mandyam, who placed in the top 10 in an international high school competition for biomedical laboratory science, is headed to Rice University to study cell biology and genetics.

Pranav Mandyam

He conducted research on acutemyeloidleukemia at Oregon Health & Science Universitys Knight Cancer Institute for two years. He was named one of the top 10 national finalists biomedical laboratory sciences by the Health Occupations Students of America. He was twice named a USA Biolympiadsemifinalist. He captained Westviews Science Olympiad Team, which made it to nationals. He volunteered at Legacy Good SamaritanHospital and received national-level recognition in multiple math competitions. He plays piano and received American College of Musicians high school diploma in social music. He is headed to Rice University, where he plans to major in biosciences with a concentration in cell biology and genetics.

Sophie Ong competed in speech and debate and did two years of research analyzing cancer genome databases and studying the impact of mRNA on tumors. At the University of California, Los Angeles, she plans to study genetics and related fields on a premed track.

Sophia Joy Ong

She competed as a member of Westviews speech and debate team. She served as co-president of Westviews chapter of Health Occupations Students of America and won that groups state championship in prepared speaking. She conducted research on cancer for two years at Oregon Health & Science University. She was also a captain of the school speech and debate team and competed at tournaments on both the state and national level. She is an avid guitar player and holds a third degree black belt in taekwondo. Shes headed to the University of California, Los Angeles, to study microbiology, immunology, and molecular genetics.

John Wang

He competed in and volunteered at many middle and high school robotics competitions, including serving as captain of his high school team. He competed as a member of Westviews varsity cross country and track teams. He was captain of the science club and president of the schools quiz bowl team, according to his profile on LinkedIn. He helped conduct research as an intern at Portland State Universitys Extreme Virus Lab. He is likely to study bioinformatics in college, National Merit officials said.

Note: If you know, or better are, one of these students, and I dont have a photo or full information, please contact me so I can make the coverage more complete.

-- Betsy Hammond; betsyhammond@oregonian.com; @chalkup

Excerpt from:
Half of Portland areas 22 top National Merit winners hail from just 2 schools - OregonLive

Imagine being able to reverse blindness, cure multiple sclerosis (MS), or rebuild your heart muscles after a heart attack. For the past few decades, research into stem cells, the building blocks of tissues and organs, has raised the prospect of medical advances of this kind yet it has produced relatively few approved treatments. But that could be about to change, says Robin Ali, professor of human molecular genetics of Kings College London. Just as gene therapy went from being a fantasy with little practical value to becoming a major area of treatment, stem cells are within a few years of reaching the medical mainstream. Whats more, developments in synthetic biology, the process of engineering and re-engineering cells, could make stem cells even more effective.

Stem cells are essentially the bodys raw material: basic cells from which all other cells with particular functions are generated. They are found in various organs and tissues, including the brain, blood, bone marrow and skin. The primary promise of adult stem cells lies in regenerative medicine, says Professor Ali.

Stem cells go through several rounds of division in order to produce specialist cells; a blood stem cell can be used to produce blood cells and skin stem cells can be used to produce skin cells. So in theory you can take adult stem cells from one person and transplant them into another person in order to promote the growth of new cells and tissue.

In practice, however, things have proved more complicated, since the number of stem cells in a persons body is relatively limited and they are hard to access. Scientists were also previously restricted by the fact that adult stem cells could only produce one specific type of cell (so blood stem cells couldnt produce skin cells, for instance).

In their quest for a universal stem cell, some scientists initially focused on stem cells from human embryos, but that remains a controversial method, not only because harvesting stem cells involves destroying the embryo, but also because there is a much higher risk of rejection of embryonic stem cells by the recipients immune system.

The good news is that in 2006 Japanese scientist Shinya Yamanaka of Kyoto University and his team discovered a technique for creating what they call induced pluripotent stem cells (iPSC). The research, for which they won a Nobel Prize in 2012, showed that you can rewind adult stem cells development process so that they became embryo-like stem cells. These cells can then be repurposed into any type of stem cells. So you could turn skin stem cells into iPSCs, which could in turn be turned into blood stem cells.

This major breakthrough has two main benefits. Firstly, because iPSCs are derived from adults, they dont come with the ethical problems associated with embryonic stem cells. Whats more, the risk of the body rejecting the cells is much lower as they come from another adult or are produced by the patient. In recent years scientists have refined this technique to the extent that we now have a recipe for making all types of cells, as well as a growing ability to multiply the number of stem cells, says Professor Ali.

Having the blueprint for manufacturing stem cells isnt quite enough on its own and several barriers remain, admits Professor Ali. For example, we still need to be able to manufacture large numbers of stem cells at a reasonable cost. Ensuring that the stem cells, once they are in the recipient, carry out their function of making new cells and tissue remains a work in progress. Finally, regulators are currently taking a hard line towards the technology, insisting on exhaustive testing and slowing research down.

The good news, Professor Ali believes, is that all these problems are not insurmountable as scientists get better at re-engineering adult cells (a process known as synthetic biology). The costs of manufacturing large numbers of stem cells are falling and this can only speed up as more companies invest in the area. There are also a finite number of different human antigens (the parts of the immune system that lead a body to reject a cell), so it should be possible to produce a bank of iPSC cells for the most popular antigen types.

While the attitude of regulators is harder to predict, Professor Ali is confident that it needs only one major breakthrough for the entire sector to secure a large amount of research from the top drug and biotech firms. Indeed, he believes that effective applications are likely in the next few years in areas where there are already established transplant procedures, such as blood transfusion, cartilage and corneas. The breakthrough may come in ophthalmology (the treatment of eye disorders) as you only need to stimulate the development of a relatively small number of cells to restore someones eyesight.

In addition to helping the body repair its own tissues and organs by creating new cells, adult stem cells can also indirectly aid regeneration by delivering other molecules and proteins to parts of the body where they are needed, says Ralph Kern, president and chief medical officer of biotechnology company BrainStorm Cell Therapeutics.

For example, BrainStorm has developed NurOwn, a cellular technology using peoples own cells to deliver neurotrophic factors (NTFs), proteins that can promote the repair of tissue in the nervous system. NurOwn works by modifying so-called Mesenchymal stem cells (MSCs) from a persons bone marrow. The re-transplanted mesenchymal stem cells can then deliver higher quantities of NTFs and other repair molecules.

At present BrainStorm is using its stem-cell therapy to focus on diseases of the brain and nervous system, such as amyotrophic lateral sclerosis (ALS, also known as Lou Gehrigs disease), MS and Huntingtons disease. The data from a recent final-stage trial suggests that the treatment may be able to halt the progression of ALS in those who have the early stage of the disease. Phase-two trial (the second of three stages of clinical trials) of the technique in MS patients also showed that those who underwent the treatment experienced an improvement in the functioning of their body.

Kern notes that MSCs are a particularly promising area of research. They are considered relatively safe, with few side effects, and can be frozen, which improves efficiency and drastically cuts down the amount of bone marrow that needs to be extracted from each patient.

Because the manufacture of MSC cells has become so efficient, NurOwn can be used to get years of therapy in one blood draw. Whats more, the cells can be reintroduced into patients bodies via a simple lumbar puncture into the spine, which can be done as an outpatient procedure, with no need for an overnight stay in hospital.

Kern emphasises that the rapid progress in our ability to modify cells is opening up new opportunities for using stem cells as a molecular delivery platform. Through taking advantage of the latest advances in the science of cellular therapies, BrainStorm is developing a technique to vary the molecules that its stem cells deliver so they can be more closely targeted to the particular condition being treated. BrainStorm is also trying to use smaller fragments of the modified cells, known as exosomes, in the hope that these can be more easily delivered and absorbed by the body and further improve its ability to avoid immune-system reactions to unrelated donors. One of BrainStorms most interesting projects is to use exosomes to repair the long-term lung damage from Covid-19, a particular problem for those with long Covid-19. Early preclinical trials show that modified exosomes delivered into the lungs of animals led to remarkable improvements in their condition. This included increasing the lungs oxygen capacity, reducing inflammation, and decreasing clotting.

Overall, while Kern admits that you cant say that stem cells are a cure for every condition, there is a lot of evidence that in many specific cases they have the potential to be the best option, with fewer side effects. With Americas Food and Drug Administration recently deciding to approve Biogens Alzheimers drug, Kern thinks that they have become much more open to approving products in diseases that are currently considered untreatable. As a result, he thinks that a significant number of adult stem-cell treatments will be approved within the next five to ten years.

Adult stem cells and synthetic biology arent just useful in treatments, says Dr Mark Kotter, CEO and founder of Bit Bio, a company spun out of Cambridge University. They are also set to revolutionise drug discovery. At present, companies start out by testing large numbers of different drug combinations in animals, before finding one that seems to be most effective. They then start a process of clinical trials with humans to test whether the drug is safe, followed by an analysis to see whether it has any effects.

Not only is this process extremely lengthy, but it is also inefficient, because human and animal biology, while similar in many respects, can differ greatly for many conditions. Many drugs that seem promising in animals end up being rejected when they are used on humans. This leads to a high failure rate. Indeed, when you take the failures into account, it has been estimated that it may cost as much to around $2bn to develop the typical drug.

As a result, pharma companies are now realising that you have to insert the human element at a pre-clinical stage by at least using human tissues, says Kotter. The problem is that until recently such tissues were scarce, since they were only available from biopsies or surgery. However, by using synthetic biology to transform adult stem cells from the skin or other parts of the body into other types of stem cells, researchers can potentially grow their own cells, or even whole tissues, in the laboratory, allowing them to integrate the human element at a much earlier stage.

Kotter has direct experience of this himself. He originally spent several decades studying the brain. However, because he had to rely on animal tissue for much of his research he became frustrated that he was turning into a rat doctor.

And when it came to the brain, the differences between human and rat biology were particularly stark. In fact, some human conditions, such as Alzheimers, dont even naturally appear in rodents, so researchers typically use mice and rats engineered to develop something that looks like Alzheimers. But even this isnt a completely accurate representation of what happens in humans.

As a result of his frustration, Kotter sought a way to create human tissues. It initially took six months. However, his company, Bit Bio, managed to cut costs and greatly accelerate the process. The companys technology now allows it to grow tissues in the laboratory in a matter of days, on an industrial scale. Whats more, the tissues can also be designed not just for particular conditions, such as dementia and Huntingdons disease, but also for particular sub-types of diseases.

Kotter and Bit Bio are currently working with Charles River Laboratories, a global company that has been involved in around 80% of drugs approved by the US Food and Drug Administration over the last three years, to commercialise this product. They have already attracted interest from some of the ten largest drug companies in the world, who believe that it will not only reduce the chances of failure, but also speed up development. Early estimates suggest that the process could double the chance of a successful trial, effectively cutting the cost of each approved drug by around 50% from $2bn to just $1bn. This in turn could increase the number of successful drugs on the market.

Two years ago my colleague Dr Mike Tubbs tipped Fate Therapeutics (Nasdaq: FATE). Since then, the share price has soared by 280%, thanks to growing interest from other drug companies (such as Janssen Biotech and ONO Pharmaceutical) in its cancer treatments involving genetically modified iPSCs.

Fate has no fewer than seven iPSC-derived treatments undergoing trials, with several more in the pre-clinical stage. While it is still losing money, it has over $790m cash on hand, which should be more than enough to support it while it develops its drugs.

As mentioned in the main story, the American-Israeli biotechnology company BrainStorm Cell Therapeutics (Nasdaq: BCLI) is developing treatments that aim to use stem cells as a delivery mechanism for proteins. While the phase-three trial (the final stage of clinical trials) of its proprietary NurOwn system for treatment of Amyotrophic lateral sclerosis (ALS, or Lou Gehrigs disease) did not fully succeed, promising results for those in the early stages of the disease mean that the company is thinking about running a new trial aimed at those patients. It also has an ongoing phase-two trial for those with MS, a phase-one trial in Alzheimers patients, as well as various preclinical programmes aimed at Parkinsons, Huntingtons, autistic spectrum disorder and peripheral nerve injury. Like Fate Therapeutics, BrainStorm is currently unprofitable.

Australian biotechnology company Mesoblast (Nasdaq: MESO) takes mesenchymal stem cells from the patient and modifies them so that they can absorb proteins that promote tissue repair and regeneration. At present Mesoblast is working with larger drug and biotech companies, including Novartis, to develop this technique for conditions ranging from heart disease to Covid-19. Several of these projects are close to being completed.

While the US Food and Drug Administration (FDA) controversially rejected Mesoblasts treatment remestemcel-L for use in children who have suffered from reactions to bone-marrow transplants against the advice of the Food and Drug Administrations own advisory committee the firm is confident that the FDA will eventually change its mind.

One stem-cell company that has already reached profitability is Vericel (Nasdaq: VCEL). Vericels flagship MACI products use adult stem cells taken from the patient to grow replacement cartilage, which can then be re-transplanted into the patient, speeding up their recovery from knee injuries. It has also developed a skin replacement based on skin stem cells.

While earnings remain relatively small, Vericel expects profitability to soar fivefold over the next year alone as the company starts to benefit from economies of scale and runs further trials to expand the range of patients who can benefit.

British micro-cap biotech ReNeuron (Aim: RENE) is developing adult stem-cell treatments for several conditions. It is currently carrying out clinical trials for patients with retinal degeneration and those recovering from the effects of having a stroke. ReNeuron has also developed its own induced pluripotent stem cell (iPSC) platform for research purposes and is seeking collaborations with other drug and biotech companies.

Like other small biotech firms in this area, it is not making any money, so it is an extremely risky investment although the rewards could be huge if any of its treatments show positive results from their clinical trials.

More here:
Investing in stem cells, the building blocks of the body - MoneyWeek

95-year-old Howard Eisenberg says he was carded recently and asked to provide proof of his age as he boarded a train on his way to visit his 80-year-old girlfriend.

Three different conductors carded me. I said, Look, isn't my gray hair enough? The conductor said, Nope, that could have started at 40. They insisted on seeing my driver's license and boy, was I proud.

Whats the secret to a long life? Three local seniors reflect on their lives and share their accomplishments and their advice to younger generations.

Born in Manhattan, Eisenberg, who now lives in Alexandria, began his lifelong career as a writer while doing a stint in the military.

I started writing at 18. WWII had just ended and my captain learned that I'd had a couple of years of college. He said, PFC Eisenberg, the Nazis who were in this barracks left a mimeograph machine and a typewriter here. Write me a newspaper to improve morale. You don't say no to your company commander, so I wrote The Rifleman."

Eisenberg, who recently completed the script for a musical, says hes been a writer ever since. I've written for radio and television. Ive written magazine articles, he said. I shared magazine and book bylines with my amazing late wife, Arlene.

To him, age is just a number and he says he has no intention of retiring. There is so much to write about that I don't plan to quit until my fingers break off in the computer keys, he said. And then I'll try dictating.

He has three children, six grandchildren and three great grandchildren. I have to do a bit of math to keep track of progeny, he jokes.

Eisenberg doesnt attribute his longevity to genetics. My mom only reached 62 and my dad his mid-70s, he said. But those were meat-and-potato days. You ate what tasted best, not what was good for you.

Instead, he attributes his good health to prioritizing nutrition and taking vitamins. A healthy diet and regular exercise are two habits that Eisenberg attributes to hitting the 95+ mark. Down with sugar and white flour, he said. The more colorful the food the better.

Broccoli, spinach, asparagus, yams and low-fat, sugar-free ice cream are among the foods that he enjoys. Of course, this is common sense, not prescription, he said.

Inquisitiveness is a trait that Eisenberg advises younger generations to acquire. One of his regrets is not being bold enough to ask questions when he didnt understand something in his youth.

I joined my outfit as an infantry replacement and they gave me a bazooka, which I'd only fired twice and that was in basic training, he said. I didn't remember how to shoot it but was sadly too embarrassed to ask guidance from one of the Battle of the Bulge seasoned veterans. Big mistake.

So when a machine gun nest stopped us and the captain shouted, Bazooka up front, I was momentarily frozen in place, continued Eisenberg. The GI carrying bazooka rockets saved me. He turned and ran to the rear with the ammo and I had to chase and tackle him. By the time I got back with the ammo the machine gun was kaput.

This experience taught him the value of seeking as much information as needed to gain the understanding necessary to complete a task.

You may not carry a bazooka, but there will be many times at different stages in your life when you won't know how to do something. Don't be a shy guy or gal. Ask questions, ask questions, ask questions. Ask until you're sure you understand. Then do it.

Adele Aspinwall Bethesda, 98

Adele Aspinwall was an English teacher in Chicago for 68 years, mostly in the inner city.

"I enjoyed looking out for and encouraging children that some people had written off," she said. "I've had so many students come back to me and tell me how I motivated them and touched their lives. That's how I knew I was born to be a teacher."

When she retired, she moved to Bethesda to be closer to her daughter, three grandchildren and five great grandchildren. Now, 98-year-old Aspinwall lives in the mother-in-laws suite in the home of her daughter.

Aspinwalls mother lived to be 87 years old and her father was 67 when he died. She believes her longevity comes from exercise and a healthy diet.

I would advise young people to begin preserving their health and develop and maintain a sense of style when they're in their 30s, said Aspinwall. Stay current with trends. I dont need to dress like a 25-year-old, but I also dont have to look frumpy. When you look well-dressed then you feel good.

Aspinwall is in a bridge club and plays regularly with a group of friends. She says this helps keep her mind sharp.

Maintain friendships and good relationships with your family members, especially your children, she said. "If thats difficult then set boundaries. But the most important thing is to stay in contact with other people. I dont focus on my age, I just focus on maintaining my health, style and relationships.

Miriam Halprin, 103 of Springfield

Miriam Halprin of Springfield is 103 and credits her longevity to eating and drinking in moderation. You need a positive mental outlook, good genes, a good laugh and an extremely high degree of vanity.

Born in Vermont, she worked as a legal secretary at Hofstra Law School. After retiring at age 75, she moved to be closer to her family which includes one son and one grandson.

These days, she spends her time reading, watching movies and playing cards to keep her mind sharp.

Halprin says her son is her greatest accomplishment, and the life advice that she would give to younger generations is, Always keep a positive outlook and a sense of humor.

Read the original post:
95 and Counting - Arlington Connection

In a recent profile, The New York Times investigates the phenomenon of cognitive super-agers people whose brains remain miraculously youthful even as they join the ranks of centenarians.

For these very few less than 1% of the United States population lives to 100, and cognitive super-agers are a fraction of that their twilight years are not marked by a sudden drop in brainpower. On the contrary, the neurofuction of cognitive super-agers doesnt change much at all after their 70th birthdays. They routinely receive top marks on tests designed to root out declines in understanding, communication, focus or memory.

How is this possible? Researchers are currently studying two methods by which cognitive super-agers are able to ward off the most common form of dementia, Alzheimers disease: via resistance or resilience. With the former, scientists say, some brains are just able to avoid damage. Genetics and lifestyle play a role. But with the latter, fascinatingly, some brains show signs of aging commiserate with Alzheimers and are able to weather the damage regardless. These people, Dr Yaakov Stern tells The New York Times, have a cognitive reserve that enables them to cope better with pathological brain changes.

Of course, longevity isnt appealing to everyone; it isnt uncommon to hear people wishing for an exit in their late seventies or early eighties, the sentiment likely influenced by watching some older relative suffer his or her way into too-old age. But as researchers unlock the secrets of societys healthiest centenarians, and people continue to live longer (the cohort aged 90 and older is Americas fastest-growing population sector), a new kind of promise might begin to perform: live quality years into your hundreds.

No one has the answers yet on how to achieve this. There seem to be some genetic predispositions that help brains that literally start out larger and stronger are less likely to atrophy (the same way a muscle in an arm shrinks due to lack of use or aging). Thickness of the cingulate cortex seems to matter, as does ones prevalence of von Economo neurons.

But both resistance and resilience, researchers believe, can be influenced by lifestyle decisions. There are things you can do right now to stick around longer (and actually have your wits about you while doing so). One of the top recommendations? Enriching experiences. That could mean pursuing higher education, working a job that requires complex problem-solving, or mastering a new craft. Also on the list protecting your hearing and vision (which are closely intertwined with cognitive function), finding a place in a supportive community, making time for leisure and play, eating a Mediterranean-style diet, and exercising regularly.

There are no guarantees here. You may not live to 100 if you do these things, and you may make it there and never remember your own name, but for now, theyre your best shot. The good news? Theyre all things you could look back on after a life lived to only 70 and know you did it right.

Thanks for reading InsideHook. Sign up for our daily newsletter and be in the know.

See the original post:
What Lifestyle Decisions Will Help You Become a "Cognitive Super-Ager"? - InsideHook